Dr. Zurita-Saavedra on Moving Therapies From mCRPC to mHSPC

Partner | Cancer Centers | <b>MD Anderson</b>

Amado J. Zurita-Saavedra, MD, discusses moving therapies utilized in metastatic castration-resistant prostate cancer into the treatment of patients with metastatic hormone-sensitive prostate cancer.

Amado J. Zurita-Saavedra, MD, assistant professor, associate professor, Department of Genitourinary Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses moving therapies utilized in metastatic castration-resistant prostate cancer (mCRPC) into the treatment of patients with metastatic hormone-sensitive prostate cancer (mHSPC).

Over time, many of the therapies approved for use in patients with mCRPC have been moved into the earlier setting of mHSPC, Zurita-Saavedra explains. These therapies include hormonal therapies and chemotherapies that were not available in mHSPC even 5 years ago.

Such shifts have resulted in significant improvements in progression-free survival and overall survival for patients with mHSPC, Zurita-Saavedra explains. Additionally, the agents have been well tolerated among patients with mHSPC, who have been able to maintain similar quality of life to that observed with the control regimens, Zurita-Saavedra concludes.